During ECTRIMS, taking place from September 11-13, 2019, in Stockholm, Sweden, EMD Serono will present 39 abstracts, including new long-term safety and efficacy data on MAVENCLAD ® (cladribine ...

BOSTON, September 12, 2024--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced presentations showcasing the long-term safety profile ...

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced 13 abstracts from the Company’s ...

Advancing the Future of Cancer Care At EMD Serono, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in ...

Data from 12 study assessments supported by EMD Serono or its affiliate, Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will focus on Rebif® (interferon beta-1a ...

Blockchain firm Nebula Genomics has announced a collaboration with EMD Serono, the North American biopharmaceutical business of Merck KGaA — the world’s oldest operating pharmaceutical firm.

EMD Serono's oncology and immuno-oncology pipeline includes more than 22 programs in early- and late-stage development, targeting a variety of difficult-to-treat cancers. Notable data presented at ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor ...

The new international data pool will be made available as early as in 2020 Pfffikon, 23 August / News Aktuell. The international associated group EMD, with headquarters in Pfffikon/Switzerland, is ...